• 
• 
• 
• 
  • Ogłoszenia
  • Plan wydawniczy
  • Regulamin ogłaszania prac
  • Zasady recenzowania i recenzenci
• 
• 
• 
• 

Wydanie 2/2011
str. 112

Bevacizumab w leczeniu proliferacji siatkówkowo-naczyniówkowych (RAP)

Bevacizumab in Retinal Angiomatous Proliferation Treatment

Maciej Bednarski¹, Sławomir Cisiecki^1,2, Janusz Michalewski^1,2, Zofia Michalewska^1,2, Jerzy Nawrocki^1,2, Dominik Odrobina^1,2

¹ Oddział Okulistyki III Szpitala Miejskiego im. K. Jonschera w Łodzi
² Klinika Okulistyczna „Jasne Błonia” w Łodzi
  Kierownik: prof. dr hab. n. med. Jerzy Nawrocki

Summary: Purpose: The best corrected visual acuity and macular retinal thickness in patients with retinal angiomatous proliferation (RAP) during anti-VEGF (bevacizumab) therapy.
Methods: A retrospective study included 12 eyes of 11 patients after intravitreal injection of 1.25 mg bevacizumab in 9 months. During monthly visits complete eye examination, assessment of the best corrected Snellen visual acuity (BCVA) and central macular thickness (CMT) in SOCT were performed. Average number of injections was 2.58.
Results: At 1, 3, 6 month BCVA improved from 0.21 (0.02-0.4) at baseline to 0.38 (0.1-0.6), 0.32 (0.04-0.6) and 0.35 (0.04-0.7), respectively. At 9 month follow-up VA was 0.31 (0.1-0.7).
Central macular thickness improved from 456.25 mm at baseline to 284.4 mm (p < 0.004) at the first month. At 3, 6 and 9 months’ follow-up improved to 300.25 mm (p < 0.01), 340.36 mm microns (p < 0.07) and 379 mm, respectively.
Conclusion: Our short-term study demonstrated that bevacizumab treatment of RAP in AMD gives encouraging results but we still need further clinical trials to specify the guidelines.

Słowa kluczowe: bevacizumab, spektralna optyczna koherentna tomografia, proliferacje siatkówkowo-naczyniówkowe.

Keywords: bevacizumab, SOCT, retinal angiomatous proliferation.

powrót